drugset / Trial / NCT06126705

18F-AlF-FAPi-04 PET/CT Imaging in Patients With Solid Tumor

NCT06126705

Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

To evaluate the potential usefulness of 18F-AlF-FAPi-04 PET/CT for the diagnosis of primary and metastatic lesions in solid cancer.

Timeline

Start
2023-07-18
Primary completion
2024-05
Completion
2024-07

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-AlF-FAPi-04 Diagnostic / imaging agent 3.7 mbq/kg Intravenous
Subject 18F-AlF-FAPi-04 Diagnostic / imaging agent 7.4 mbq/kg Intravenous
Subject 18F-FDG Diagnostic / imaging agent

Indications

No indication recorded.